 |
 |
 |
 |
 |
 |
 |
|
|
NCCN Non-Small Cell Lung Cancer Guidelines UpdateA presentation from the NCCN 13th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida. Presenters David S. Ettinger, MD David S. Ettinger, MD Dr. Ettinger has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the activity. He has served as a consultant, scientific advisor, and product/speakers’ bureau member for AstraZeneca Pharmaceuticals Corporation; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Merck & Co., Inc.; MGI PHARMA, Inc.; Pfizer Inc.; and sanofi-aventis U.S. He has also served as a scientific advisor for Genentech, Inc. and has received grant/research support from Bayer HealthCare Pharmaceuticals; Genentech, Inc.; and Pharmion Corporation. Dr. Ettinger has indicated that his presentation will not include discussion of investigational or unlabeled uses of commercial products. Mark G. Kris, MD Dr. Kris has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products or devices to be discussed in this activity or who may financially support the activity. He has served as a consultant for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, and Pfizer Inc. He has also received grant/research support from sanofi-aventis U.S. Dr. Kris has indicated that his presentation will include discussion of investigational or unlabeled uses of commercial products. Program Goal The goal of this program is to provide participants with increased knowledge regarding the management of patients with non-small cell lung cancer and discuss the innovative therapies and treatment methods. Educational Objectives Following this activity, participants should be able to:
Intended Audience This educational activity is designed to meet the educational needs of physicians, nurses, and other clinical professionals who manage patients with cancer. Activity Instructions Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than May 16, 2009. There is no fee for participating in this activity. Accreditation Information Physicians The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. NCCN designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Nurses This activity is approved for 0.7 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity. Release date: May 16, 2008 Commercial Support Funded in part by an educational grant from Eli Lilly and Company
|
|
NCCN 1st Annual Forum: Innovative Diagnostics & Therapeutics in Cancer Care™ |
|
|
